Promoting
Safe & Effective
Wound Bed Preparation
Our Story
The company was born in 2017 as a spin-off from BRAIN Biotech AG, a leading German biotech company that focuses on harnessing biological diversity to develop innovative solutions.
Andy Weymann MD, MBA
Chairman
François Fournier
Director
Based in the US, François is CEO & President of HTL Biotechnology and was formerly CEO Virbac Corp. Having served as head of Wound Care at Smith & Nephew, following multiple leadership roles around the world at Nestle Skin Health & Abbott, François brings not only deep woundcare insight but also broad, global experience in pharmaceutical and multi-business environments.
Riad Armanious
Director
Riad is the CEO of Eva Pharma, one of the leading specialty pharma companies in Africa. Riad is active in the YPO (Young Presidents Association), the “T20” foundation and Vice Chairman in the Egyptian Industrial Chamber of Pharmaceuticals.
Adriaan Moelker
Director
Adriaan is the CEO of BRAIN Biotech AG. Before joining BRAIN Biotech AG, he held a wide variety of management positions during his 35-year career with a particular focus on enzymes and Biotechnology.
Dan Wright
Director
Dan is a highly experienced executive, Chair and board member of public and private companies. Dan was previously a founding partner at NorthEdge Capital, a UK Private Equity firm following an investment career at Callahan Associates, Deutsche Bank and RBS. He serves as SolasCure’s independent Board member.
Jane Hart
Director
Jane is a highly experienced executive in clinical operations and affairs, with more than 25 years of experience in the clinical research industry, including serving as Vice President, Global Clinical Development at 3M. A leader in drug and device research, Jane brings deep experience of shepherding products from concept through to global approvals to Solascure.
Frank Goebel
Director
Frank is the former CFO of BRAIN Biotech AG and was co-CEO at SymbioPharm. Frank brings long executive experience in bio-based industries to Solascure. Prior experience at RBS and ING.
Mission & Values
SolasCure is a pioneering biologics company committed to addressing the pressing issue of inadequate debridement, biofilm disruption, and healing solutions for chronic wounds.
Patient-focused
we strive to deliver better wound care treatments for patients, improving outcomes and quality of life
Practical & Adoptable
we work closely with leading clinicians and providers to ensure our cutting edge products can be readily adopted within standards of care and have the largest impact possible
Evidence-based medicine
our scientific programme aims to provide targeted therapies that demonstrably relieve suffering and improve outcomes for patients, clinicians and health systems
